Your institution may have access to this item. Find your institution then sign in to continue.
Title
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Authors
Comi, G; Abramsky, O; Arbizu, T; Boyko, A; Gold, R; Havrdová, E; Komoly, S; Selmaj, K; Sharrack, B; Filippi, M; LAQ/5063 Study Group
Abstract
Laquinimod, an oral novel immunomodulator, was shown to reduce MRI-measured disease activity in relapsing-remitting MS (RRMS) patients.